SAN DIEGO, Jan. 29, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock, offered at a price to the public of $20.00 per share. The gross ... 4 Traders, 5 hours ago
Mirati Therapeutics Announces Proposed Public Offering of Common Stock - 4 Traders, 21 hours ago
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock - BioSpace, 19 hours ago
2 images for "mirati"
Oncology company Mirati Therapeutics The company said it will provide the underwriters with a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Mirati Therapeutics added that there can ...BusinessWeek, 4 hours ago
Document Format Files Seq Description Document Type Size 1 AMENDMENT NO. 1 f127150sc13ga1.htm SC 13G/A 122509 Complete submission text fileSEC, 1 day ago 424B5 - Mirati Therapeutics, Inc. (0001576263) (Filer) SEC, 21 hours ago
Poltu was born to a poor Brahmin family in a village called Mirati, 1935, in Birbhum district of West Bengal. His father, a schoolmaster, was frequently in and out of jail as he served the greater cause of Indian freedom from British colonialism.Economic Times, 1 month ago
Mirati Therapeutics Inc ($MRTX) was among the biggest gainers on the Russell 2000 for Tuesday January 27 as the stock popped 5.43% to $20.98, representing a gain of $1.08 per share. Some 36,742 shares traded hands on 261 trades, compared with an ...Equities.com, 1 day ago Mirati Therapeutics Inc (MRTX) Drops 5.46% on January 21 Equities.com, 1 week ago Mirati Therapeutics Inc (MRTX) Hits New 52-week Low During December 01 Session Equities.com, 1 month ago
Mirati Therapeutics (NASDAQ:MRTX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the six brokers that cover the stock, Zacks Investment Research reports. Six research analysts have rated the stock with a strong buy rating.Ticker Report, 2 days ago Brokerages Anticipate Mirati Therapeutics to Post ($1.00) EPS (NASDAQ:MRTX) Mideast Time, 1 week ago
US-based oncology firm Mirati Therapeutics has started dosing patients in an investigator-sponsored Phase II clinical trial of mocetinostat to treat relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The ...Pharmaceutical Business Review, 3 weeks ago MIRATI THERAPEUTICS : begins dosing in Phase II trial of mocetinostat to treat bladder cancer 4 Traders, 2 weeks ago Mirati begins dosing in Phase II trial of mocetinostat to treat bladder cancer Pharmaceutical Business Review, 3 weeks ago Mirati Therapeutics : starts dosing in Phase II trial of mocetinostat to treat non-Hodgkin's lymphoma 4 Traders, 3 weeks ago
Filed Under: Analysts Price Targets • Market News Research analysts at Piper Jaffray raised their price target on shares of Mirati Therapeutics (NASDAQ:MRTX) from $31.00 to $37.00 in a report released on Monday. The firm currently has an ...American Banking News, 1 month ago
at 13:20 PM EST Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called ...Fat Pitch Financials, 1 month ago
Who Doubts Yellen's Policies? Summers for One ( BBG ) Samsung, Apple Back in Dead Heat for Global Smartphone Dominance ( WSJ ) Islamic State purportedly sets new deadline for hostage swap ( Reuters ) Turkey's $7.9 Billion Mystery Money That's ...Zero Hedge, 5 hours ago
on your WebpageAdd Widget >Get your members hooked!